6.55

2.83% 0.18

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $6.55, with a volume of 2.02M. It is up +2.83% in the last 24 hours and down -5.07% over the past month. Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Previous Close:

$6.37

Open:

$6.37

24h Volume:

2.02M

Relative Volume:

1.64

Market Cap:

$687.03M

Revenue:

Net Income/Loss:

$-58.88M

P/E Ratio:

-5.8882

EPS:

-1.1124

Net Cash Flow:

$-42.79M

1W Performance:

+4.47%

1M Performance:

-5.07%

6M Performance:

+45.56%

1Y Performance:

+825.01%

1-Day Range:

$6.27

$6.585

1-Week Range:

$6.22

$6.97

52-Week Range:

$0.52

$8.00

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2026-08-06

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD vs MOBBW, SHMD, GOODO, PSNYW, DWLD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	2.45	3.33B	0	0	0	0.00
SHMD Schmid Group N V	6.19	397.06M	52.15M	-21.46M	0	-0.4675
GOODO Gladstone Commercial Corporation	20.19	372.90M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	2.83	254.39M	2.07B	-1.42B	-1.37B	-0.6765
DWLD Davis Select Worldwide ETF	47.19	0	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Initiated	Piper Sandler	Overweight
Jan-23-26	Resumed	Leerink Partners	Outperform
Dec-22-25	Initiated	Jefferies	Buy
Nov-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

Jun 13, 2026

Relmada Therapeutics bolsters Sepranolone Program with Michael Quirk as Senior Advisor - Indian Pharma Post

Jun 13, 2026

Jun 11, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program - Investing News Network

Jun 11, 2026

Relmada appoints Michael Quirk as senior advisor for sepranolone - Investing.com

Jun 11, 2026

Relmada appoints Michael Quirk as senior advisor for sepranolone By Investing.com - Investing.com UK

Jun 11, 2026

Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire

Jun 11, 2026

Jun 09, 2026

Venrock-affiliated funds hold 6.2% of Relmada (NASDAQ: RLMD) - Stock Titan

Jun 09, 2026

Jun 07, 2026

RLMD Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesSurprise Factor Analysis - newsline.com

Jun 07, 2026

Jun 04, 2026

RLMD: NDV-01 advances to phase III with strong data, broadening access and maintaining solid financials - TradingView

Jun 04, 2026

Jun 03, 2026

RLMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 03, 2026

Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Mov - Benzinga

Jun 03, 2026

Jun 01, 2026

Relmada executives to present at Jefferies healthcare conference - Investing.com UK

May 28, 2026

Relmada TherapeuticsIncreases authorized common stock to 200 million shares from 150 million - marketscreener.com

May 28, 2026

Relmada (NASDAQ: RLMD) holders back higher share cap and equity plan - Stock Titan

May 28, 2026

Relmada executives to present at Jefferies healthcare conference By Investing.com - Investing.com Australia

May 28, 2026

Relmada Therapeutics (RLMD) to Present at the Jefferies Global Healthcare Conference - StreetInsider

May 28, 2026

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire

May 28, 2026

Relmada Therapeutics Increases Authorized Shares After Shareholder Vote - TipRanks

May 28, 2026

May 27, 2026

Relmada Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

May 27, 2026

Relmada Therapeutics (RLMD) Edges Higher as Stock Holds Above Key SupportForce Index - newsline.com

May 27, 2026

May 22, 2026